Skip to main content

Advertisement

SpringerLink
Log in

Gelatinase B (−1562C/T) polymorphism in tumor progression and invasion of breast cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Matrix metalloproteinases (MMPs) play an important role in breast cancer tumor invasion and progression. MMP-9 is a member of the MMP family and is also known as Gelatinase B or type IV collagenases (92 kDa) and possesses proteolytic activity against type IV collagen, a major component of the basement membrane. Our study aims to examine the association of Gelatinase B (−1562C > T) promoter polymorphism with breast cancer invasion and progression. The study involves 200 breast cancer patients and age-matched 191 healthy controls. The SNP-1562C > T (rs3918242) in MMP-9 promoter region was examined by allele-specific polymerase chain reaction and gel electrophoresis. The genotypes were determined and compared between patients and controls, and the influence of the polymorphism on clinicopathological data was analyzed. The T allele of the -1562C > T MMP-9 polymorphism was detected more frequently in breast cancer patients than controls (p < 0.001). Our results suggest the clinical importance of MMP-9 gene polymorphism (−1562C > T) in breast cancer patients. The study may also help in identifying individuals at risk of developing breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

MMP-9:

Matrix metalloproteinase-9

SNP:

Single nucleotide polymorphism

AS-PCR:

Allele-specific polymerase chain reaction

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Gaurav A, Pooja R, Ernesto R, Sa'nchez F, Jorge Carrasco R'n, Juan Manuel C, et al. Breast cancer care in developing countries. World J Surg. 2009;33:2069–76.

    Article  Google Scholar 

  3. Agarwal G, Ramakant P. Breast cancer care in India: the current scenario and the challenges for the future. Breast Care. 2008;3:21–7.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Byrne C, Brinton LA, Haile RW, Schairer C. Heterogeneity of the effect of family history on breast cancer risk. Epidemiology. 1991;2:276–84.

    Article  CAS  PubMed  Google Scholar 

  5. Smith P, McGuffog L, Douglas F, Easton, et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer. 2006;45:646–55.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Pakseresht S, Ingle GK, Bahadur AK, Ramteke VK, Singh MM, Garg S, et al. Risk factors with breast cancer among women in Delhi. Indian J Cancer. 2009;46:132–8.

    Article  CAS  PubMed  Google Scholar 

  7. Althuis DM, Dozier JM, Anderson FW, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality. Int J Epidemiol. 1973–1997; 34:405–12.

    Google Scholar 

  8. Maller O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia. 2010;15:301–18.

    Article  PubMed  Google Scholar 

  9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  PubMed  Google Scholar 

  10. Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol. 1999;77:465–80.

    Article  CAS  PubMed  Google Scholar 

  11. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995;55:1856–62.

    CAS  PubMed  Google Scholar 

  12. Chaudhary AK et al. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res Rev. 2013;753(1):7–23. doi:10.1016/j.mrrev.2013.01.002.

    Article  CAS  Google Scholar 

  13. Jed F. Fisher, Shahriar Mobashery. Recent advances in MMP inhibitor design, Cancer Metastasis Rev.2006; 115–36.

  14. Ajay Kumar Chaudhary, Mamta Singh, Alok C Bharti, Kamlesh Asotra, Shanthy Sundaram and Ravi Mehrotra. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck, J Biol Chem. 2010; 17–10.

  15. Nagase H, Woessner Jr JF. Matrix metalloproteinase. J Biol Chem. 1999;274:21491–4.

    Article  CAS  PubMed  Google Scholar 

  16. Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol. 1997;183:377–9.

    Article  CAS  PubMed  Google Scholar 

  17. McDonnell S, Navre M, Coffey Jr RJ, Matrisian LM. Expression and localization of matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4:527–33.

    Article  CAS  PubMed  Google Scholar 

  18. Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT. Functional −1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med. 2007;36:409–14.

    Article  CAS  PubMed  Google Scholar 

  19. Wu J, Zhang L, Luo H, Zhu Z, Zangh C, Hou Y. Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol. 2008;27:553–7.

    Article  CAS  PubMed  Google Scholar 

  20. Liu Z, Li L, Yang Z, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Kallakury BV et al. Increased expression of Matrix metalloproteinase 2 & 9 and tissue inhibitors of matrix metalloproteinase 1 & 2 correlates with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113–9.

    CAS  PubMed  Google Scholar 

  22. Baker EA, Leaper DJ. Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol. 2002;28:24–9.

    Article  CAS  PubMed  Google Scholar 

  23. Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003;89:2116–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol. 2003;24:417–20.

    CAS  PubMed  Google Scholar 

  25. Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer. 2004;100:356–65.

    Article  CAS  PubMed  Google Scholar 

  26. Lahiri DK, Nurnberger Jr JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Raković MŽA, Stanković A. Allele-specific detection of C-1562T polymorphism in the matrix metalloproteinase-9 gene: genotyping by MADGE. Clin Biochem. 2006;39:630–2.

    Article  PubMed  Google Scholar 

  28. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000;6:149–56.

    Article  CAS  PubMed  Google Scholar 

  29. Venkateshwari AK, Sri M, Krishnaveni D, Pratibha N, Vidyasagar A, Jyothy A. Role of plasma MMP 9 levels in the pathogenesis of chronic pancreatitis. Ind J Clin Biochem. 2011;26:136–9.

    Article  CAS  Google Scholar 

  30. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and −9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;87:287–97.

    Article  CAS  PubMed  Google Scholar 

  31. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathological features and survival. Clin Med Res. 2009;7:4–13.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52:261–88.

    Article  CAS  PubMed  Google Scholar 

  33. Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev. 2001;25:16–31.

    CAS  PubMed  Google Scholar 

  34. Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 2003;9:899–04.

    CAS  PubMed  Google Scholar 

  35. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788–94.

    Article  CAS  PubMed  Google Scholar 

  36. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer. 2003;39:981–8.

    Article  CAS  PubMed  Google Scholar 

  37. Zhou Y, Chunyuan Y, Miao X, Tan W, Liang G, Xiong P, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2004;25:399–04.

    Article  CAS  PubMed  Google Scholar 

  38. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–33.

    Article  CAS  PubMed  Google Scholar 

  39. Srivastava P, Mandhani A, Kapoor R, Mittal RD. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol. 2010;17:3068–75.

    Article  PubMed  Google Scholar 

  40. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006;95:65–72.

    Article  CAS  PubMed  Google Scholar 

  41. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26:3579–83.

    CAS  PubMed  Google Scholar 

  42. Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002;41:289–96.

    Article  CAS  PubMed  Google Scholar 

  43. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271:10672–80.

    Article  CAS  PubMed  Google Scholar 

  44. Shibao TK, Tsurudome Y, Hirata K, Nagata N, Itoh H. Lymphatic microvessel density is an independent prognostic factor in colorectal cancer. Dis Colon Rectum. 2007;50:308–14.

    Article  PubMed  Google Scholar 

  45. Shu Y. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res. 2006;69:636–45.

    Article  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the University Grants Commission (UGC), Rajeev Gandhi National Fellowship (RGNF), New Delhi, India; Department of Bio-Technology (DBT), Osmania University-Inter Disciplinary School for Life Science for Advance Research and Education (ISLARE), New Delhi; and UGC Center for Advanced Studies (CAS) II, New Delhi.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Genetics, Osmania University, Hyderabad, Andhra Pradesh, 500 007, India

    P. Chiranjeevi, K. Mrudula Spurthi, N. Santhoshi Rani, G. Rajesh Kumar, T. Mohini Aiyengar, M. Saraswati, G. Srilatha, G. Kishore Kumar, S. Vishnupriya & H. Surekha Rani

  2. M.N.J Institute of Oncology & Regional Cancer Centre, Red Hills, Hyderabad, Andhra Pradesh, India

    Sudha Sinha, C. Sanjeeva Kumari & B. Nagarjuna Reddy

Authors
  1. P. Chiranjeevi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Mrudula Spurthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Santhoshi Rani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Rajesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Mohini Aiyengar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Saraswati
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Srilatha
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Kishore Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sudha Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Sanjeeva Kumari
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Nagarjuna Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S. Vishnupriya
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H. Surekha Rani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Surekha Rani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiranjeevi, P., Spurthi, K.M., Rani, N.S. et al. Gelatinase B (−1562C/T) polymorphism in tumor progression and invasion of breast cancer. Tumor Biol. 35, 1351–1356 (2014). https://doi.org/10.1007/s13277-013-1181-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1181-5

Keywords

Search

Navigation